In the current study, the cross talk among the Notch1 pathway, Ets-1, and TRPA1 in erythroid and megakaryocyte differentiation suggests a potential combinatorial strategy for treatment of hematological malignancies in the near future. The gene discussed is NOTCH1; the disease is hematologic disorder.